Scleroderma

 Diagnosis and assessment of progression is based on clinical findings, particularly the appearance and extent of skin involvement.

Antinuclear antibodies (especially centromere antibodies) and extractable nuclear antigen antibodies (especially Scl 70) and RNA polymerase 3 antibodies to differentiate between diffuse and limited forms of disease.

Creatinine, urea as baseline measurements.

Renal biopsy or biopsy of other sites, as appropriate, to assess disease complications.

See also Connective tissue diseases